14505-80-7Relevant academic research and scientific papers
Enantiospecific Synthesis of (+)-(2R)- and (-)-(2S)-6-Ethyl-3,4-dihydro-2-methyl-4-oxo-2H-pyran-5-carboxylic Acid
Deschenaux, Pierre-Francois,Kallimopoulos, Thomas,Stoeckli-Evans, Helen,Jacot-Guillarmod, Andre
, p. 731 - 737 (1989)
The two enantiomers (-)-(2S)- and (+)-(2R)-6-ethyl-3,4-dihydro-2-methyl-4-oxo-2H-pyran-5-carboxylic acid ((S)- and (R)-7) have been synthesized from (+)-(3S) and (-)-(3R)-3-hydroxybutanoates, respectively (Scheme 1).By reduction and decarboxylation, the tetrahydro-2H-pyranols (2R,4R,6S)- and (2S,4S,6R)-13, respectively, were obtained with an enantiomeric excess of >/= 93 percent.
Optimization of Orally Bioavailable PI3KδInhibitors and Identification of Vps34 as a Key Selectivity Target
Henley, Zo? A.,Amour, Augustin,Barton, Nick,Bantscheff, Marcus,Bergamini, Giovanna,Bertrand, Sophie M.,Convery, Máire,Down, Kenneth,Dümpelfeld, Birgit,Edwards, Chris D.,Grandi, Paola,Gore, Paul M.,Keeling, Steve,Livia, Stefano,Mallett, David,Maxwell, Aoife,Price, Mark,Rau, Christina,Reinhard, Friedrich B. M.,Rowedder, James,Rowland, Paul,Taylor, Jonathan A.,Thomas, Daniel A.,Hessel, Edith M.,Hamblin, J. Nicole
supporting information, p. 638 - 655 (2020/02/04)
Optimization of a lead series of PI3Kδinhibitors based on a dihydroisobenzofuran core led to the identification of potent, orally bioavailable compound 19. Selectivity profiling of compound 19 showed similar potency for class III PI3K, Vps34, and PI3Kδ, and compound 19 was not well-tolerated in a 7-day rat toxicity study. Structure-based design led to an improvement in selectivity for PI3Kδover Vps34 and, a focus on oral phramacokinetics properties resulted in the discovery of compound 41, which showed improved toxicological outcomes at similar exposure levels to compound 19.
INHIBITOR OF BTK AND MUTANTS THEREOF
-
, (2020/09/12)
The disclosure includes compounds of Formula (I) (1) wherein Q0, Q1, Q2, Q3, Q4, Z, W, i, j, m, n, Warhead, R0, R1, R3, R4, R5, R6, and R7, are defined herein. Also disclosed is a method for treating a neoplastic disease, autoimmune disease, and inflammatory disorder with these compounds.
Discovery of MK-6169, a Potent Pan-Genotype Hepatitis C Virus NS5A Inhibitor with Optimized Activity against Common Resistance-Associated Substitutions
Yu, Wensheng,Tong, Ling,Selyutin, Oleg,Chen, Lei,Hu, Bin,Zhong, Bin,Hao, Jinglai,Ji, Tao,Zan, Shuai,Yin, Jingjun,Ruck, Rebecca T.,Curry, Stephanie,McMonagle, Patricia,Agrawal, Sony,Rokosz, Laura,Carr, Donna,Ingravallo, Paul,Bystol, Karin,Lahser, Frederick,Liu, Rong,Chen, Shiying,Feng, Kung-I,Cartwright, Mark,Asante-Appiah, Ernest,Kozlowski, Joseph A.
, p. 3984 - 4003 (2018/05/14)
We describe the discovery of MK-6169, a potent and pan-genotype hepatitis C virus NS5A inhibitor with optimized activity against common resistance-associated substitutions. SAR studies around the combination of changes to both the valine and aminal carbon region of elbasvir led to the discovery of a series of compounds with substantially improved potency against common resistance-associated substitutions in the major genotypes, as well as good pharmacokinetics in both rat and dog. Through further optimization of key leads from this effort, MK-6169 (21) was discovered as a preclinical candidate for further development.
HYDROXYL PURINE COMPOUNDS AND USE THEREOF
-
Paragraph 0164; 0167; 0168, (2018/06/09)
Disclosed are a series of hydroxyl purine compounds and the use thereof as PDE2 or TNFα inhibitors, in particular, the compounds as shown in formula (I), or tautomers or pharmaceutically acceptable salts thereof.
COMPOUNDS AND THEIR USE AS BACE INHIBITORS
-
Page/Page column 155; 156, (2016/05/02)
The present application relates to compounds of formula (I), (la), or (lb) and their pharmaceutical compositions/preparations. This application further relates to methods of treating or preventing Αβ-related pathologies such as Down's syndrome, β- amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI ("mild cognitive impairment"), Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with diseases such as Alzheimer's disease or dementia, including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease.
PIPERAZINE DERIVATIVES AS HIV PROTEASE INHIBITORS
-
, (2015/10/05)
The present invention is directed to compounds of Formula I pharmaceutical compositions comprising the same, and their use in the inhibition of HIV protease, the inhibition of HIV replication, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS.
A Scalable Synthesis of (R,R)-2,6-Dimethyldihydro-2H-pyran-4(3H)-one
Young, Ian S.,Haley, Matthew W.,Tam, Annie,Tymonko, Steven A.,Xu, Zhongmin,Hanson, Ronald L.,Goswami, Animesh
, p. 1360 - 1368 (2015/11/02)
A scalable synthesis of (R,R)-2,6-dimethyldihydro-2H-pyran-4(3H)-one is reported. Key to this strategy is the Ti(OiPr)4-catalyzed Kulinkovich cyclopropanation of silyl protected (R)-ethyl 3-hydroxybutanoate, and subsequent oxidative fragmentati
HETEROCYCLE-SUBSTITUED TETRACYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR TREATMENT OF VIRAL DISEASES
-
, (2014/08/06)
The present invention relates to novel Heterocycle-Substituted Tetracyclic Compounds of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein A, A', R 2 R 3, R 4 and R are as defined herein. The present i
THIAZOLYL-SUBSTITUED TETRACYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR TREATMENT OF VIRAL DISEASES
-
, (2014/08/06)
The present invention relates to novel Thiazolyl-Substituted Tetracyclic Compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein A, A', R2R3, R4 and R5 are as defined herein. The present
